The DOI matches its Crossref record; 21 of the 22 references it cites were found in a registry or an index.
Effects of Intravenous Ketamine on Explicit and Implicit Measures of Suicidality in Treatment-Resistant Depression
Open accessAbstract
Background Intravenous ketamine has shown rapid antidepressant effects in early trials, making it a potentially attractive candidate for depressed patients at imminent risk of suicide. The Implicit Association Test (IAT), a performance-based measure of association between concepts, may have utility in suicide assessment.Methods Twenty-six patients with treatment-resistant depression were assessed using the suicidality item of the Montgomery-Asberg Depression Rating Scale (MADRS-SI) 2 hours before and 24 hours following a single subanesthetic dose of intravenous ketamine. Ten patients also completed IATs assessing implicit suicidal associations at comparable time points. In a second study, nine patients received thrice-weekly ketamine infusions over a 12-day period.Results Twenty-four hours after a single infusion, MADRS-SI scores were reduced on average by 2.08 points on a 0 to 6 scale (p < .001; d = 1.37), and 81% of patients received a rating of 0 or 1 postinfusion. Implicit suicidal associations were also reduced following ketamine (p = .003; d = 1.36), with reductions correlated across implicit and explicit measures. MADRS-SI reductions were sustained for 12 days by repeated-dose ketamine (p < .001; d = 2.42).Conclusions These preliminary findings support the premise that ketamine has rapid beneficial effects on suicidal cognition and warrants further study.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Ketamine's half-life in the body is ;2 h (Autry et al., 2011), yet a single low-dose treatment elicits sustained (.1 week) antidepressant effects in patients (Berman et al., 2000;Zarate et al., 2006;Price et al., 2009), strongly suggesting it induces neuroplasticity (Duman, 2018).”
From Psychedelics and Neural Plasticity: Therapeutic Implications (2022) · cites this paper as Price et al., 2009
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Ketamine rapidly induces flexibility in implicit representations of self on the Implicit Association Test 134,135 , and these shifts correlated with self-reported symptom improvements 110 , suggesting that ketamine can immediately impact the structure of implicit mental representations relevant to one's concept of self, a core form of cognitive bias in depression.”
From Neuroplasticity in cognitive and psychological mechanisms of depression: an integrative model (2020) · cites this paper as [135]
In the citing paper
“Critically, several versions of the IAT have also been incorporated into clinical ketamine trials, which found that the “escape” version of the IAT (instead of “death,” the participant links the self with “escape” or “stay”) was associated with reductions in SI (57, 58).”
From New methods for assessing rapid changes in suicide risk (2021) · cites this paper as [57]
In the citing paper
“Administration of glutamate receptor antagonists, such as the NMDA antagonist, ketamine, have potent antidepressant effects especially in treatment resistant depressed patients”
From Inflammatory cytokines in depression: neurobiological mechanisms and therapeutic implications (2013) · cites this paper as Price et al., 2009
In the citing paper
“Recent studies report that ketamine also reduces suicide ideation, a major advance over typical antidepressants with low efficacy and delayed onset of action151,152.”
From Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants (2016) · cites this paper as [152]
In the citing paper
“Ketamine has been also shown to induce a rapid amelioration of suicidal ideation in major depressed patients 23, 24”
From Mechanisms of ketamine action as an antidepressant (2018) · cites this paper as [23]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Statistical Power Analysis for the Behavioral Sciences
Muller, K. E., & Cohen, J. (1989) · Technometrics · doi:10.2307/1270020 · Cited by 99,603
Statistical power analysis for the behavioral sciences
Cohen, J. (1990) · Computers Environment and Urban Systems · doi:10.1016/0198-9715(90)90050-4 · Cited by 65,417
A new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962
Measuring individual differences in implicit cognition: the implicit association test
Greenwald, A. G., McGhee, D. E., & Schwartz, J. L. K. (1998) · Journal of Personality and Social Psychology · doi:10.1037/0022-3514.74.6.1464 · Cited by 9,210
Understanding and using the Implicit Association Test: I. An improved scoring algorithm.
Greenwald, A. G., Nosek, B. A., & Banaji, M. R. (2003) · Journal of Personality and Social Psychology · doi:10.1037/0022-3514.85.2.197 · Cited by 5,815
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856
Self-citationA randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
Self-citationUnderstanding and using the Implicit Association Test: III. Meta-analysis of predictive validity.
Greenwald, A. G., Poehlman, T. A., Uhlmann, E. L., & Banaji, M. R. (2009) · Journal of Personality and Social Psychology · doi:10.1037/a0015575 · Cited by 3,257
The Inventory of Depressive Symptomatology (IDS): Psychometric properties
Rush, A. J., Gullion, C. M., Basco, M. R., Jarrett, R. B., & Trivedi, M. H. (1996) · Psychological Medicine · doi:10.1017/s0033291700035558 · Cited by 2,177
Understanding and Using the Implicit Association Test: II. Method Variables and Construct Validity
Nosek, B. A., Greenwald, A. G., & Banaji, M. R. (2004) · Personality and Social Psychology Bulletin · doi:10.1177/0146167204271418 · Cited by 1,216
Cited by
Sorted by citations
Items 501–600 of 601
Ketamine for negative and depressive symptoms in schizophrenia: the evidence so far
Diendorfer, C., Bum, C., Weidenauer, A., Sauerzopf, U., Bartova, L., Dajic, I., Müller, L., Rujescu, D., Praschak-Rieder, N., & Willeit, M. (2026) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2026.1766485 · Cited by 1
Treatment of the psychiatric patient
Chepenik, L. G., & Mallory, M. N. S. (2013) · Cambridge University Press eBooks · doi:10.1017/cbo9781139088077.026 · Cited by 2
Kluge, I., Ahrens, K., Wohltmann, T., Kircher, T. T. J., & Konrad, C. (2013) · Clinical Neurophysiology · doi:10.1016/j.clinph.2013.04.198 · Cited by 1
Ketamine in treatment-resistant depression: A review of completed investigations
Verma, S. (2015) · Journal of Mahatma Gandhi Institute of Medical Sciences · doi:10.4103/0971-9903.151741 · Cited by 1
Blocking NMDA receptor at rest: a possible alleviation of depression
Lü, W. (2011) · Acta Pharmacologica Sinica · doi:10.1038/aps.2011.113 · Cited by 1
Baghai, T. C., Blier, P., Baldwin, D. S., Bauer, M., Fountoulakis, K. Ν., Kasper, S. F., Leonard, B. E., Stein, D. J., & Versiani, M. (2011) · Cited by 1
Branch, P., Mathews, D. C., Richards, E. M., Niciu, M. J., Ionescu, D. F., Rasimas, J. J., & Zarate, C. A. (2013) · Cited by 1
Ducasse, D., Girod, C., & Courtet, P. (2016) · Springer eBooks · doi:10.1007/978-3-319-26282-6_10 · Cited by 1
Ketamine-Based Treatment of MDD: A Biologist’s Perspective
Li, S., Zhang, Y., & Zhou, Q. (2017) · Journal of Depression And Therapy · doi:10.14302/issn.2476-1710.jdt-17-1673
Kowalski, L., Delanogare, E., & de Oliveira, T. B. (2021) · VITTALLE - Revista de Ciências da Saúde · doi:10.14295/vittalle.v33i3.13224 · Cited by 1
Betzler, F., & Majić, T. (2017) · Springer eBooks · doi:10.1007/978-3-642-55125-3_48 · Cited by 1
Potential Suicide Prophylactic Activity by the Fish Oil Metabolite, 4-Hydroxyhexenal
Kalkman, H. O. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23136953 · Cited by 1
Kétamine et suicidalité : modèles animaux pour comprendre son mécanisme d’action
Nguyen, T. M. L., Jollant, F., Tritschler, L., Colle, R., Corruble, E., & Gardier, A. M. (2023) · Annales Pharmaceutiques Françaises · doi:10.1016/j.pharma.2023.10.008 · Cited by 2
Ibrahim, W., Yang, Y., & Matuskey, D. (2024) · Psychiatry Research Case Reports · doi:10.1016/j.psycr.2024.100228 · Cited by 1
Bærentzen, S., Thomsen, J., Thomsen, M., Jakobsen, S., Simonsen, M. I., Wegener, G., Brooks, D. J., & Landau, A. (2024) · Synapse · doi:10.1002/syn.22294 · Cited by 1
Selek, S., & Soares, J. C. (2017) · Springer eBooks · doi:10.1007/978-981-10-6577-4_19 · Cited by 2
Sachdev, R. A., Ruparelia, R., Reid, J. E., Mpavenda, D., Cinosi, E., & Fineberg, N. A. (2018) · Cambridge University Press eBooks · doi:10.1017/9781108164313.016 · Cited by 1
Recent Advances in Ketamine Research: An Update
Raj, T. Y., & Ren, Q. (2020) · Open Journal of Anesthesiology · doi:10.4236/ojanes.2020.103008 · Cited by 1
Biological theories of suicidal behaviour
Turecki, G. (2021) · doi:10.1093/med/9780198834441.003.0022 · Cited by 1
Ketamine in Psychiatric Disorders
Danyeli, L. V., Götting, F. N., Şen, Z. D., Li, M., & Walter, M. (2022) · Springer eBooks · doi:10.1007/978-3-030-62059-2_420 · Cited by 1
The Interactive Effects of Ketamine and Magnesium Upon Depressive-like Pathology
Razmjou, S. (2014) · Carleton University's Institutional Repository (MacOdrum Library, Carleton University) · doi:10.22215/etd/2014-10484 · Cited by 1
N-Methyl-d-Aspartate (NMDA) Antagonists for the Treatment of Depression
Skolnick, P., Popik, P., & Trullás, R. (2010) · Birkhäuser Basel eBooks · doi:10.1007/978-3-0346-0241-9_1 · Cited by 1
Postoperative Central Nervous System Changes in Elderly Surgical Patients
Silverstein, J. H. (2012) · Springer eBooks · doi:10.1007/978-1-4614-3888-5_21
Antidepressants and Morphological Plasticity of Monoamine Neurons
Nakamura, S. (2012) · InTech eBooks · doi:10.5772/37593
Ketamine: An Old Anesthetic, A New Antidepressant
Karacaer, F. (2014) · Psikiyatride Guncel Yaklasimlar - Current Approaches in Psychiatry · doi:10.5455/cap.20140430125304
Rapidly acting treatment in the emergency department
Heller, R. A., & Byrne, L. E. (2013) · Cambridge University Press eBooks · doi:10.1017/cbo9781139088077.033
Future perspectives on the pharmacological management of depression
Yates, S., Smith, E., Alhaj, H. A., & McAllister-Williams, H. (2013) · Clinical Investigation · doi:10.4155/cli.12.152
Highlights from the latest articles in suicide research
Antypa, N., & Serretti, A. (2014) · Personalized Medicine · doi:10.2217/pme.14.13
Neurosciences et psychiatrie en 2009 : vers une convergence transdisciplinaire ?
Gourion, D. (2010) · L information psychiatrique · doi:10.1684/ipe.2010.0658
NMDA Antagonism in the treatment of Major Depressive Disorder
Chalikiopoulos, A. P. A. (2013) · Utrecht University Repository (Utrecht University)
Rapid Antidepressant Action of Ketamine in Psychiatric Patients with Suicidality - a Case Series
Raj, R., & Kumar, R. (2014) · American Journal of Medical Sciences and Medicine · doi:10.12691/ajmsm-2-2-4
Experimental Pharmacologic Approaches for the Reduction of Suicidal Ideation and Behavior
Ballard, E. D., Richards, E. M., Ionescu, D. F., Niciu, M. J., Voort, J. V., & Zarate, C. A. (2014) · Springer eBooks · doi:10.1007/978-3-319-09964-4_12
Boram, C. (2015) · Digital Access to Scholarship at Harvard (DASH) (Harvard University)
Emotional stroop performance in older adults
Price, R. B. (2011) · Rutgers University Community Repository (Rutgers University) · doi:10.7282/t35b01jp
Self-citationSpecific modalities of treatment
McGrath, P. J., & Roose, S. P. (2013) · Cambridge University Press eBooks · doi:10.1017/cbo9781139175869.024
Ketamin als Antidepressivum: Die aktuelle Studienlage
Ritter, P. S., Bauer, M., & Pilhatsch, M. (2014) · Der Nervenarzt
(2016) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/s-0042-114245
Implisitt assosiasjonstest, selvskading og selvmordsatferd
Vallevik, I. Ø. (2011) · Duo Research Archive (University of Oslo)
Ketamin: Yeni Bir Antidepresan? Ketamine: A New Antidepressant?
Karacaer, F. (2015)
Ketamine Usage at Subanesthetic Doses and Psychoactive Effects
Flack, D., & Dakwar, E. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-800212-4.00063-7
Douleur morale, douleur physique : des mécanismes neurobiologiques à la prise en charge
Gaillard, A. (2013) · Elsevier eBooks · doi:10.1016/b978-2-294-73727-5.00007-6
Extracurricular Involvement and Anxiety in Relation to Suicide Ideation among College Students
Floyd, P. N. (2016) · TopSCHOLAR (Western Kentucky University)
Ketamine: The Glutamatergic Antidepressant and Its Efficacy
Tracy, D. K., Caddy, C., & Shergill, S. S. (2016) · Springer eBooks · doi:10.1007/978-81-322-2803-5_41
Emerging Data for Ketamine in Obsessive-Compulsive, Stress-Related, and Substance Use Disorders
Rodríguez, C. I., & Dakwar, E. (2016) · Springer eBooks · doi:10.1007/978-3-319-42925-0_9
Lorenzini, N. (2016) · UCL Discovery (University College London)
Serafini, G., Hayley, S. P., Ghasemi, M., & Amore, M. (2017) · Wiley eBooks · doi:10.1002/9783527803781.ch11
La découverte des propriétés antidépressives de la kétamine
de Maricourt, P., & Raphaël Gaillard, B. (2017) · Annales Médico-psychologiques revue psychiatrique · doi:10.1016/j.amp.2017.07.006
Increased Activity of GABA(A) Receptors Contributes to Postanesthetic Memory Deficits
Zurek, A. A. (2015) · TSpace (University of Toronto)
Nuwal, K., Jain, S., & Rathore, K. S. (2018) · Pharmatutor · doi:10.29161/pt.v6.i6.2018.24
Kim, J., & 정남운 (2019) · Korean Journal of Health Psychology · doi:10.17315/kjhp.2019.24.3.001 · Cited by 1
Glutamate Modulators in Major Depressive Disorder
Cooper, T. M., & Iosifescu, D. V. (2019) · Elsevier eBooks · doi:10.1016/b978-0-323-58131-8.00013-6
Effects of Ketamine on Pain and Depression Comorbidity
Tang, X.-H., & Yang, J. (2020) · Springer eBooks · doi:10.1007/978-981-15-2902-3_9
Rapidly Acting Treatment in the ED for Psychiatric Patients
Wilson, M. P., & Heller, R. A. (2021) · Springer eBooks · doi:10.1007/978-3-030-52520-0_26
Evaluation of the antidepressant potential of dextromethorphan
Nguyen, L. (2015) · The Research Repository @ WVU (West Virginia University) · doi:10.33915/etd.6309
Ketamine in Psychiatric Disorders
Danyeli, L. V., Götting, F. N., Şen, Z. D., Li, M., & Walter, M. (2021) · Springer eBooks · doi:10.1007/978-3-319-56015-1_420-1 · Cited by 1
Niittymäki, E. (2021) · Työväentutkimus Vuosikirja
Using Implicit and Explicit Measures to Predict Suicidal Behavior Among Adolescents
Tezanos, K. M., Bell, K., & Cha, C. B. (2021) · Springer eBooks · doi:10.1007/978-3-030-82465-5_10
The use of psychoactive substances in the treatment of mental disorders
Karaś-Ruszczyk, K., Groblińska, K., Szczygieł, K., & Samochowiec, J. (2021) · Alcoholism and Drug Addiction · doi:10.5114/ain.2021.111791
Betzler, F., & Majić, T. (2016) · Springer eBooks · doi:10.1007/978-3-642-55214-4_48-1
Jain, S. B. (2012) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.14267300.15779493
Rapid-Acting Antidepressants and Underlying Mechanisms
Wilson, S. E., Chen, M., & Darji, H. (2016) · International Journal of Public Health Science (IJPHS) · doi:10.11591/.v5i4.4828
A KETAMIN HATÁSA A TERÁPIAREZISZTENS MAJOR DEPRESSZIÓRA
SZTE BTK, P. I., & Peszeki, N. (2017) · Psychologia Hungarica Caroliensis · doi:10.12663/psyhung.5.2017.1.3
Spanagel, R., & Sommer, W. H. (2012) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.11807956.15303056
Estudio post-mortem de las alteraciones en la expresión de RNA en el cerebro de pacientes suicidasPreprint
Cabrera‐Mendoza, B. (2020) · Thesis Commons (OSF Preprints) · doi:10.31237/osf.io/cmvjb
(2009) · Biological Psychiatry · doi:10.1016/s0006-3223(09)01314-6
Kalra, H., Dean, O. M., Dodd, S., & Berk, M. (2012) · doi:10.2217/ebo.11.273
Mattis, P. J., Fridman, C. B., & Meltzer, E. P. (2019) · Clinical handbooks in neuropsychology · doi:10.1007/978-3-319-93497-6_35
Rawal, B., & Ballanyi, K. (2022) · Brain Sciences · doi:10.3390/brainsci12070945
Schnell wirksame Antidepressiva
Şen, Z. D., Danyeli, L. V., & Walter, M. (2022) · Springer eBooks · doi:10.1007/978-3-662-65734-8_10
Jamal, S., Kar, S. K., & Singh, A. K. (2023) · Psychiatry Research Case Reports · doi:10.1016/j.psycr.2023.100119
Cigognini, M. A. (2023) · doi:10.11606/t.5.2023.tde-10052023-120550
Álvaro Cavieres, F., & López‐Silva, P. (2022) · Revista médica de Chile · doi:10.4067/s0034-98872022001101513
Rao, P., & Morandini, H. A. E. (2023) · Journal of Indian Association for Child and Adolescent Mental Health · doi:10.1177/09731342231179036
Schwartz, T. L. (2023) · Global Journal of Medical Case Reports · doi:10.31586/gjmcr.2023.809
Reis, H. S. (2024) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.47.2024.tde-09042024-161136
Ahuja, J., & Leontieva, L. (2024) · Case Reports in Psychiatry · doi:10.1155/2024/2143372
Medications for Depression: Monoamine Enhancers and Esketamine (Antidepressants)
Park, S., & Shen, W. W. (2024) · Springer eBooks · doi:10.1007/978-3-030-51366-5_133
Gillespie, C. F., & Nemeroff, C. B. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-19176-3.00046-7
Nist, A. N., Walsh, S. J., & Shahan, T. A. (2025) · Psychopharmacology · doi:10.1007/s00213-025-06794-y
Les troubles psychiatriques résistants
Holtzmann, J. (2015) · Presses universitaires de Grenoble eBooks · doi:10.3917/pug.bouv.2015.01.0135
Ketamine/esketamine for treatment-resistant depression
Nikayin, S., & Sanacora, G. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-824067-0.00013-x · Cited by 3
Human in vivo assessment of ketamine binding of the serotonin transporter—follow up at a higher dose
Schlosser, G., Murgaš, M., Godbersen, G. M., Reichel, S., Silberbauer, L., Nics, L., Winkler, D., Stimpfl, T., Hacker, M., Kasper, S. F., et al. (2025) · Frontiers in Neuroscience · doi:10.3389/fnins.2025.1651016
Sanspara, M. M., Shah, D., Shah, S. H., Desai, N. D., Shah, S., & Patel, P. S. (2025) · Indian Journal of Psychological Medicine · doi:10.1177/02537176251389117
Ketamine: The illicit party psychedelic that promises to heal depression
Melanson, B. A. (2019) · doi:10.64628/aam.4kwqfdmc6
Kétamine : la drogue festive illicite qui promet de guérir la dépression
Melanson, B. A. (2019) · doi:10.64628/aap.aqr9ntpfg
Menon, T., Lu, A., Arulmozhi, A., Dri, C., Wong, S., Teopiz, K., Le, G.-H., Lee, S., Weissman, C. R., & McIntyre, R. (2026) · Psychiatry Research · doi:10.1016/j.psychres.2026.117036 · Cited by 1
Ji, Y., Chen, X., Zheng, Q., Liu, Q., Zhang, C., Zhang, T.-T., & Li, L.-J. (2026) · World Journal of Psychiatry · doi:10.5498/wjp.v16.i3.113825
Duncan, E., Hersant, H., & Khairova, R. A. (2026) · Springer eBooks · doi:10.1007/978-3-032-15772-0_4
Potentialisation de la réponse antidépressive par la lumière : étude préclinique
Delcourte, S. (2019) · theses.fr (ABES) · doi:10.70675/7468b6d3zbf12z4888z88afzc63efcc91723
Prise en charge médicamenteuse des patients souffrant de douleur chronique réfractaire
Corriger, A. (2019) · theses.fr (ABES) · doi:10.70675/668e4777zf8d0z4bdcz9780z0f91fedfe2b6
Tezanos, K. M., Simeone, A., Gerson, R. S., Baroni, A., Spirito, A., & Cha, C. B. (2026) · Child Psychiatry & Human Development · doi:10.1007/s10578-026-02006-6
Ketamine Use in Critically Ill Patients: Insights into Depressive Symptoms and Hemodynamic Changes
Patel, V., Sujanyal, S. A., Raavi, L., Blumenfeld, S. G., Saleem, F., Bateh, S., Hanson, A., Jena, A., Isha, S., Kunze, K. L., et al. (2026) · Journal of Intensive Care Medicine · doi:10.1177/08850666261438474
Zhang, L., Xiong, Z., Chen, S., Zhu, Q., Wang, Y., Lu, Q., Bu, X., Xia, A., Chen, L., Chen, C., et al. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6c00391
Intravenous Ketamine in Suicidal Ideation in Depression
Jatal, R., Samarth, A., & Deulkar, S. (2026) · Journal of Medical Excellence · doi:10.4103/jome.jome_17_25
Pinzi, M., Cuomo, A., Rescalli, M. B., Pierini, C., & Fagiolini, A. M. (2026) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2026.2714839
Borkowska, M., Witaszczyk, M., Sołtan, A., Wiktorzak, N., Lipska, J., Prządka, J., Kochan-Olszewska, D., Rudnicki, L., Pawlicki, J., Laskus, J., et al. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.3(51).2026.6636
Hu, B., Ortiz-Cruz, A., Sachidanandan, R. F., Ramiro, C., & Bourgeois, J. A. (2026) · Journal of the Academy of Consultation-Liaison Psychiatry · doi:10.1016/j.jaclp.2026.09.005
BindingDB Entry 50011888: Repurposing of Drugs-The Ketamine Story.
BindingDB (2022) · UC San Diego · doi:10.7270/q2t15797
Metadata
- Authors
- Price, R. B., Nock, M. K., Charney, D. S., & Mathew, S. J.
- Affiliations
- Rutgers, The State University of New Jersey (US)
- Harvard University (US)
- Icahn School of Medicine at Mount Sinai (US)
- Corresponding author
- Price, Rebecca B.
- Venue
- Biological Psychiatry
- Publisher
- Elsevier BV
- Published
- 2009-09
- Volume
- 66
- Issue
- 5
- Pages
- 522-526
- ISSN
- 0006-3223 (ISSN-L)
- PMC
- PMC2935847
- OpenAlex
- W2118815581
- Cited by
- 600
- References
- 22
- Citations by year
- 2026: 15 · 2025: 16 · 2024: 18 · 2023: 25 · 2022: 43 · 2021: 49 · 2020: 43 · 2019: 39 · 2018: 31 · 2017: 34 · 2016: 46 · 2015: 62 · 2014: 45 · 2013: 42 · 2012: 43
- FWCI
- 21.80
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Biological Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- Funders
- National Institutes of Health (F31 MH081468, K23-MH-069656, MO1-RR-00071)
- National Alliance for Research on Schizophrenia and Depression
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Social Sciences › Psychology › Clinical Psychology › Suicide and Self-Harm Studies
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Keywords
- intravenous ketamine, treatment-resistant depression, suicidality, suicide risk, Implicit Association Test, rapid antidepressant effects, suicide assessment
- MeSH terms
- Suicide Prevention, Depression, Drug Resistance, Female, Humans, Infusions, Intravenous, Ketamine, Male, Middle Aged, Psychiatric Status Rating Scales, Suicide, Cohort Studies, Excitatory Amino Acid Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
